Sun Pharma Q4 Profit Rises 26% YoY, US Sales Dip Slightly

$SUNPHARMA 📰 Key Highlights Net Profit: ₹27B vs ₹21.5B YoY → +26% growth (slightly below estimate of ₹28B). Revenue: ₹66B vs ₹55.9B YoY → +18% growth. EBITDA: ₹10.1B vs ₹7.7B YoY → +31% growth. EBITDA Margin: 15.31% vs 13.76% YoY → margin expansion of ~155 bps. US Formulation Sales: $459M, lower by 1.1% YoY. 📊 Fundamentals & Ratios PE Ratio (TTM): ~32x (vs pharma sector average ~28x). ROE: ~14%. Debt-to-Equity: ~0.3 (healthy balance sheet). Dividend Yield: ~1.2%. 💊 Business Focus Strong growth in India formulations and specialty products. US sales dipped slightly, reflecting pricing pressure in generics. Expanding in specialty therapies (dermatology, ophthalmology, oncology). Focus on R&D pipeline and global partnerships. ⚠️ Risks Pricing pressure in US generics market. Regulatory risks (FDA inspections, compliance). Currency volatility impacting exports. Dependence on specialty product approvals for growth. 📈 Outlook Domestic market strength continues to drive growth. Specialty portfolio expected to offset US generics weakness. Margin expansion trend encouraging for sustained profitability. Sun Pharma remains India’s largest pharma company, with strong global presence.